{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:51:56Z","timestamp":1790650316937,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"44","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,11,2]]},"DOI":"10.1038\/onc.2017.200","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T15:07:38Z","timestamp":1499699258000},"page":"6132-6142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Cellular prion protein (PrPC) in the development of Merlin-deficient tumours"],"prefix":"10.1038","volume":"36","author":[{"given":"L","family":"Provenzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D A","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lyons-Rimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E A","family":"Maze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C L","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Rigby-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ammoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C O","family":"Hanemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"issue":"Pt 3","key":"BFonc2017200_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/brain\/awm249","volume":"131","author":"CO Hanemann","year":"2008","unstructured":"Hanemann CO . Magic but treatable? Tumours due to loss of merlin. Brain 2008; 131 (Pt 3): 606\u2013615.","journal-title":"Brain"},{"key":"BFonc2017200_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli AM, Fernandez-Valle C . Role of Merlin\/NF2 inactivation in tumor biology. Oncogene 2016; 35: 537\u2013548.","journal-title":"Oncogene"},{"key":"BFonc2017200_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajmg.a.34359","volume":"158A","author":"JO Blakeley","year":"2012","unstructured":"Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 2012; 158A: 24\u201341.","journal-title":"Am J Med Genet A"},{"key":"BFonc2017200_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1006\/nbdi.1998.0179","volume":"5","author":"C Rosenbaum","year":"1998","unstructured":"Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Mueller HW, Hanemann CO . Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis 1998; 5: 55\u201364.","journal-title":"Neurobiol Dis"},{"key":"BFonc2017200_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/onc.2012.587","volume":"33","author":"S Ammoun","year":"2014","unstructured":"Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA et al. Axl\/Gas6\/NFkappaB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene 2014; 33: 336\u2013346.","journal-title":"Oncogene"},{"key":"BFonc2017200_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.molonc.2014.08.005","volume":"9","author":"S Ammoun","year":"2015","unstructured":"Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M, Hanemann CO . The p53\/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours. Mol Oncol 2015; 9: 236\u2013248.","journal-title":"Mol Oncol"},{"key":"BFonc2017200_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","volume":"140","author":"W Li","year":"2010","unstructured":"Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L et al. Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010; 140: 477\u2013490.","journal-title":"Cell"},{"key":"BFonc2017200_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1593\/neo.111060","volume":"13","author":"L Zhou","year":"2011","unstructured":"Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA, Hanemann CO . Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt\/beta-catenin signaling linked to the PDGFR\/Src and Rac\/PAK pathways. Neoplasia 2011; 13: 1101\u20131112.","journal-title":"Neoplasia"},{"key":"BFonc2017200_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1365-2990.2006.00769.x","volume":"32","author":"CO Hanemann","year":"2006","unstructured":"Hanemann CO, Bartelt-Kirbach B, Diebold R, Kampchen K, Langmesser S, Utermark T . Differential gene expression between human schwannoma and control Schwann cells. Neuropathol Appl Neurobiol 2006; 32: 605\u2013614.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"BFonc2017200_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bbadis.2007.02.011","volume":"1772","author":"L Westergard","year":"2007","unstructured":"Westergard L, Christensen HM, Harris DA . The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 2007; 1772: 629\u2013644.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2017200_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0306-4522(02)00155-0","volume":"113","author":"MJ Ford","year":"2002","unstructured":"Ford MJ, Burton LJ, Morris RJ, Hall SM . Selective expression of prion protein in peripheral tissues of the adult mouse. Neuroscience 2002; 113: 177\u2013192.","journal-title":"Neuroscience"},{"key":"BFonc2017200_CR12","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1073\/pnas.0511290103","volume":"103","author":"AD Steele","year":"2006","unstructured":"Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD . Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci USA 2006; 103: 3416\u20133421.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017200_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nn.2483","volume":"13","author":"J Bremer","year":"2010","unstructured":"Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 2010; 13: 310\u2013318.","journal-title":"Nat Neurosci"},{"key":"BFonc2017200_CR14","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1128\/MCB.01040-09","volume":"30","author":"R Stella","year":"2010","unstructured":"Stella R, Massimino ML, Sandri M, Sorgato MC, Bertoli A . Cellular prion protein promotes regeneration of adult muscle tissue. Mol Cell Biol 2010; 30: 4864\u20134876.","journal-title":"Mol Cell Biol"},{"key":"BFonc2017200_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/19336896.2015.1027855","volume":"9","author":"TG Santos","year":"2015","unstructured":"Santos TG, Lopes MH, Martins VR . Targeting prion protein interactions in cancer. Prion 2015; 9: 165\u2013173.","journal-title":"Prion"},{"key":"BFonc2017200_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1152\/physrev.00007.2007","volume":"88","author":"R Linden","year":"2008","unstructured":"Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR . Physiology of the prion protein. Physiol Rev 2008; 88: 673\u2013728.","journal-title":"Physiol Rev"},{"key":"BFonc2017200_CR17","first-page":"8042","volume":"8","author":"L Zeng","year":"2015","unstructured":"Zeng L, Zou W, Wang G . Cellular prion protein (PrP(C)) and its role in stress responses. Int J Clin Exp Med 2015; 8: 8042\u20138050.","journal-title":"Int J Clin Exp Med"},{"key":"BFonc2017200_CR18","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1158\/0008-5472.CAN-07-5849","volume":"68","author":"S Ammoun","year":"2008","unstructured":"Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO . Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 2008; 68: 5236\u20135245.","journal-title":"Cancer Res"},{"key":"BFonc2017200_CR19","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/onc.2011.357","volume":"31","author":"S Ammoun","year":"2011","unstructured":"Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA et al. Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival. Oncogene 2011; 31: 1710\u20131722.","journal-title":"Oncogene"},{"key":"BFonc2017200_CR20","doi-asserted-by":"publisher","first-page":"9683","DOI":"10.1073\/pnas.0308413101","volume":"101","author":"B Fevrier","year":"2004","unstructured":"Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M et al. Cells release prions in association with exosomes. Proc Natl Acad Sci USA 2004; 101: 9683\u20139688.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017200_CR21","doi-asserted-by":"publisher","first-page":"35973","DOI":"10.1074\/jbc.M109.051086","volume":"284","author":"MV Guillot-Sestier","year":"2009","unstructured":"Guillot-Sestier MV, Sunyach C, Druon C, Scarzello S, Checler F . The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J Biol Chem 2009; 284: 35973\u201335986.","journal-title":"J Biol Chem"},{"key":"BFonc2017200_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.molimm.2007.04.030","volume":"45","author":"C Zuber","year":"2008","unstructured":"Zuber C, Knackmuss S, Rey C, Reusch U, Rottgen P, Frohlich T et al. Single chain Fv antibodies directed against the 37\u2009kDa\/67\u2009kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2008; 45: 144\u2013151.","journal-title":"Mol Immunol"},{"key":"BFonc2017200_CR23","doi-asserted-by":"publisher","first-page":"24457","DOI":"10.1038\/srep24457","volume":"6","author":"D Sarnataro","year":"2016","unstructured":"Sarnataro D, Pepe A, Altamura G, De Simone I, Pesapane A, Nitsch L et al. The 37\/67\u2009kDa laminin receptor (LR) inhibitor, NSC47924, affects 37\/67\u2009kDa LR cell surface localization and interaction with the cellular prion protein. Sci Rep 2016; 6: 24457.","journal-title":"Sci Rep"},{"key":"BFonc2017200_CR24","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1523\/JNEUROSCI.3526-13.2014","volume":"34","author":"I Klyubin","year":"2014","unstructured":"Klyubin I, Nicoll AJ, Khalili-Shirazi A, Farmer M, Canning S, Mably A et al. Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Abeta synaptotoxicity. J Neurosci 2014; 34: 6140\u20136145.","journal-title":"J Neurosci"},{"key":"BFonc2017200_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14728220903431069","volume":"14","author":"Y Lin","year":"2010","unstructured":"Lin Y, Bai L, Chen W, Xu S . The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010; 14: 45\u201355.","journal-title":"Expert Opin Ther Targets"},{"key":"BFonc2017200_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.canlet.2011.02.040","volume":"306","author":"YH Yap","year":"2011","unstructured":"Yap YH, Say YH . Resistance against apoptosis by the cellular prion protein is dependent on its glycosylation status in oral HSC-2 and colon LS 174T cancer cells. Cancer Lett 2011; 306: 111\u2013119.","journal-title":"Cancer Lett"},{"key":"BFonc2017200_CR27","doi-asserted-by":"publisher","first-page":"14955","DOI":"10.1073\/pnas.011578098","volume":"98","author":"J Ma","year":"2001","unstructured":"Ma J, Lindquist S . Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci USA 2001; 98: 14955\u201314960.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017200_CR28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6","volume":"77","author":"B Deguen","year":"1998","unstructured":"Deguen B, Goutebroze L, Giovannini M, Boisson C, van der NR, Jaurand MC et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer 1998; 77: 554\u2013560.","journal-title":"Int J Cancer"},{"key":"BFonc2017200_CR29","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1128\/MCB.25.6.2384-2394.2005","volume":"25","author":"GH Xiao","year":"2005","unstructured":"Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 2005; 25: 2384\u20132394.","journal-title":"Mol Cell Biol"},{"key":"BFonc2017200_CR30","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1158\/0008-5472.CAN-05-1628","volume":"66","author":"MA Gerber","year":"2006","unstructured":"Gerber MA, Bahr SM, Gutmann DH . Protein 4.1B\/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res 2006; 66: 5295\u20135303.","journal-title":"Cancer Res"},{"key":"BFonc2017200_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cancergencyto.2005.04.003","volume":"162","author":"F Nunes","year":"2005","unstructured":"Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov AO, Ramesh V et al. Inactivation patterns of NF2 and DAL-1\/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 2005; 162: 135\u2013139.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFonc2017200_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cancergencyto.2008.01.020","volume":"183","author":"K Wozniak","year":"2008","unstructured":"Wozniak K, Piaskowski S, Gresner SM, Golanska E, Bieniek E, Bigoszewska K et al. BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. Cancer Genet Cytogenet 2008; 183: 14\u201320.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFonc2017200_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10048-011-0300-y","volume":"13","author":"P van den Munckhof","year":"2012","unstructured":"van den Munckhof P, Christiaans I, Kenter SB, Baas F, Hulsebos TJ . Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 2012; 13: 1\u20137.","journal-title":"Neurogenetics"},{"key":"BFonc2017200_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10014-016-0271-7","volume":"33","author":"S Yuzawa","year":"2016","unstructured":"Yuzawa S, Nishihara H, Tanaka S . Genetic landscape of meningioma. Brain Tumor Pathol 2016; 33: 237\u2013247.","journal-title":"Brain Tumor Pathol"},{"key":"BFonc2017200_CR35","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.4161\/cc.9.22.13838","volume":"9","author":"W Li","year":"2010","unstructured":"Li W, Giancotti FG . Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1). Cell Cycle 2010; 9: 4433\u20134436.","journal-title":"Cell Cycle"},{"key":"BFonc2017200_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.febslet.2012.03.016","volume":"586","author":"L Zhou","year":"2012","unstructured":"Zhou L, Hanemann CO . Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett 2012; 586: 1403\u20131408.","journal-title":"FEBS Lett"},{"key":"BFonc2017200_CR37","doi-asserted-by":"publisher","first-page":"11170","DOI":"10.1074\/jbc.M312105200","volume":"279","author":"ET Parkin","year":"2004","unstructured":"Parkin ET, Watt NT, Turner AJ, Hooper NM . Dual mechanisms for shedding of the cellular prion protein. J Biol Chem 2004; 279: 11170\u201311178.","journal-title":"J Biol Chem"},{"key":"BFonc2017200_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-1326-6-36","volume":"6","author":"HC Altmeppen","year":"2011","unstructured":"Altmeppen HC, Prox J, Puig B, Kluth MA, Bernreuther C, Thurm D et al. Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo. Mol Neurodegener 2011; 6: 36.","journal-title":"Mol Neurodegener"},{"key":"BFonc2017200_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1750-3639.2003.tb00034.x","volume":"13","author":"T Utermark","year":"2003","unstructured":"Utermark T, Kaempchen K, Hanemann CO . Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins. Brain Pathol 2003; 13: 352\u2013363.","journal-title":"Brain Pathol"},{"key":"BFonc2017200_CR40","first-page":"57","volume":"26","author":"J Weise","year":"2008","unstructured":"Weise J, Doeppner TR, Muller T, Wrede A, Schulz-Schaeffer W, Zerr I et al. Overexpression of cellular prion protein alters postischemic Erk1\/2 phosphorylation but not Akt phosphorylation and protects against focal cerebral ischemia. Restor Neurol Neurosci 2008; 26: 57\u201364.","journal-title":"Restor Neurol Neurosci"},{"key":"BFonc2017200_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4161\/pri.21914","volume":"6","author":"RJ Arsenault","year":"2012","unstructured":"Arsenault RJ, Li Y, Potter A, Griebel PJ, Kusalik A, Napper S . Induction of ligand-specific PrP (C) signaling in human neuronal cells. Prion 2012; 6: 477\u2013488.","journal-title":"Prion"},{"key":"BFonc2017200_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.micpath.2007.08.014","volume":"44","author":"XM Zhou","year":"2008","unstructured":"Zhou XM, Xu GX, Zhao DM . In vitro effect of prion peptide PrP 106-126 on mouse macrophages: possible role of macrophages in transport and proliferation for prion protein. Microb Pathog 2008; 44: 129\u2013134.","journal-title":"Microb Pathog"},{"key":"BFonc2017200_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1083\/jcb.200803013","volume":"181","author":"DB Parkinson","year":"2008","unstructured":"Parkinson DB, Bhaskaran A, rthur-Farraj P, Noon LA, Woodhoo A, Lloyd AC et al. c-Jun is a negative regulator of myelination. J Cell Biol 2008; 181: 625\u2013637.","journal-title":"J Cell Biol"},{"key":"BFonc2017200_CR44","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1074\/jbc.M104345200","volume":"277","author":"Y Gu","year":"2002","unstructured":"Gu Y, Fujioka H, Mishra RS, Li R, Singh N . Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP. J Biol Chem 2002; 277: 2275\u20132286.","journal-title":"J Biol Chem"},{"key":"BFonc2017200_CR45","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/sj.onc.1208335","volume":"24","author":"VA Robb","year":"2005","unstructured":"Robb VA, Gerber MA, Hart-Mahon EK, Gutmann DH . Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene 2005; 24: 1946\u20131957.","journal-title":"Oncogene"},{"key":"BFonc2017200_CR46","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339: 1077\u20131080.","journal-title":"Science"},{"key":"BFonc2017200_CR47","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1111\/j.1462-5822.2007.00950.x","volume":"9","author":"S Bourteele","year":"2007","unstructured":"Bourteele S, Oesterle K, Weinzierl AO, Paxian S, Riemann M, Schmid RM et al. Alteration of NF-kappaB activity leads to mitochondrial apoptosis after infection with pathological prion protein. Cell Microbiol 2007; 9: 2202\u20132217.","journal-title":"Cell Microbiol"},{"key":"BFonc2017200_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1189\/jlb.1102521","volume":"74","author":"SM Bacot","year":"2003","unstructured":"Bacot SM, Lenz P, Frazier-Jessen MR, Feldman GM . Activation by prion peptide PrP106-126 induces a NF-kappaB-driven proinflammatory response in human monocyte-derived dendritic cells. J Leukoc Biol 2003; 74: 118\u2013125.","journal-title":"J Leukoc Biol"},{"key":"BFonc2017200_CR49","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1074\/jbc.M115.684258","volume":"291","author":"BB Guo","year":"2016","unstructured":"Guo BB, Bellingham SA, Hill AF . Stimulating the release of exosomes increases the intercellular transfer of prions. J Biol Chem 2016; 291: 5128\u20135137.","journal-title":"J Biol Chem"},{"key":"BFonc2017200_CR50","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood-2005-02-0802","volume":"107","author":"C Robertson","year":"2006","unstructured":"Robertson C, Booth SA, Beniac DR, Coulthart MB, Booth TF, McNicol A . Cellular prion protein is released on exosomes from activated platelets. Blood 2006; 107: 3907\u20133911.","journal-title":"Blood"},{"key":"BFonc2017200_CR51","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.mcn.2005.12.003","volume":"31","author":"J Faure","year":"2006","unstructured":"Faure J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B et al. Exosomes are released by cultured cortical neurones. Mol Cell Neurosci 2006; 31: 642\u2013648.","journal-title":"Mol Cell Neurosci"},{"key":"BFonc2017200_CR52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1042\/BC20080025","volume":"100","author":"S Alais","year":"2008","unstructured":"Alais S, Simoes S, Baas D, Lehmann S, Raposo G, Darlix JL et al. Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Biol Cell 2008; 100: 603\u2013615.","journal-title":"Biol Cell"},{"key":"BFonc2017200_CR53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/cc.8.1.7506","volume":"8","author":"JP Lopes","year":"2009","unstructured":"Lopes JP, Oliveira CR, Agostinho P . Cdk5 acts as a mediator of neuronal cell cycle re-entry triggered by amyloid-beta and prion peptides. Cell Cycle 2009; 8: 97\u2013104.","journal-title":"Cell Cycle"},{"key":"BFonc2017200_CR54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0002-9440(10)64517-8","volume":"157","author":"J Satoh","year":"2000","unstructured":"Satoh J, Kuroda Y, Katamine S . Gene expression profile in prion protein-deficient fibroblasts in culture. Am J Pathol 2000; 157: 59\u201368.","journal-title":"Am J Pathol"},{"key":"BFonc2017200_CR55","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1096\/fj.06-7799com","volume":"21","author":"J Liang","year":"2007","unstructured":"Liang J, Pan Y, Zhang D, Guo C, Shi Y, Wang J et al. Cellular prion protein promotes proliferation and G1\/S transition of human gastric cancer cells SGC7901 and AGS. FASEB J 2007; 21: 2247\u20132256.","journal-title":"FASEB J"},{"key":"BFonc2017200_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.nbd.2009.09.017","volume":"37","author":"S Ammoun","year":"2010","unstructured":"Ammoun S, Ristic N, Matthies C, Hilton DA, Hanemann CO . Targeting ERK1\/2 activation and proliferation in human primary schwannoma cells with MEK1\/2 inhibitor AZD6244. Neurobiol Dis 2010; 37: 141\u2013146.","journal-title":"Neurobiol Dis"},{"key":"BFonc2017200_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.virusres.2015.02.004","volume":"207","author":"SF Godsave","year":"2015","unstructured":"Godsave SF, Peters PJ, Wille H . Subcellular distribution of the prion protein in sickness and in health. Virus Res 2015; 207: 136\u2013145.","journal-title":"Virus Res"},{"key":"BFonc2017200_CR58","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1089\/ars.2009.2628","volume":"12","author":"N Singh","year":"2010","unstructured":"Singh N, Singh A, Das D, Mohan ML . Redox control of prion and disease pathogenesis. Antioxid Redox Signal 2010; 12: 1271\u20131294.","journal-title":"Antioxid Redox Signal"},{"key":"BFonc2017200_CR59","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1093\/emboj\/20.21.5863","volume":"20","author":"S Gauczynski","year":"2001","unstructured":"Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, Rieger R et al. The 37-kDa\/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001; 20: 5863\u20135875.","journal-title":"EMBO J"},{"key":"BFonc2017200_CR60","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.bbadis.2007.05.001","volume":"1772","author":"JC Watts","year":"2007","unstructured":"Watts JC, Westaway D . The prion protein family: diversity, rivalry, and dysfunction. Biochim Biophys Acta 2007; 1772: 654\u2013672.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2017200_CR61","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1096\/fj.11-185579","volume":"26","author":"D Loubet","year":"2012","unstructured":"Loubet D, Dakowski C, Pietri M, Pradines E, Bernard S, Callebert J et al. Neuritogenesis: the prion protein controls beta1 integrin signaling activity. FASEB J 2012; 26: 678\u2013690.","journal-title":"FASEB J"},{"key":"BFonc2017200_CR62","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/j.1460-9568.2005.04080.x","volume":"21","author":"J Carimalo","year":"2005","unstructured":"Carimalo J, Cronier S, Petit G, Peyrin JM, Boukhtouche F, Arbez N et al. Activation of the JNK-c-Jun pathway during the early phase of neuronal apoptosis induced by PrP106-126 and prion infection. Eur J Neurosci 2005; 21: 2311\u20132319.","journal-title":"Eur J Neurosci"},{"key":"BFonc2017200_CR63","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1083\/jcb.200307132","volume":"164","author":"DB Parkinson","year":"2004","unstructured":"Parkinson DB, Bhaskaran A, Droggiti A, Dickinson S, D'Antonio M, Mirsky R et al. Krox-20 inhibits Jun-NH2-terminal kinase\/c-Jun to control Schwann cell proliferation and death. J Cell Biol 2004; 164: 385\u2013394.","journal-title":"J Cell Biol"},{"key":"BFonc2017200_CR64","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/his.12062","volume":"62","author":"A Shivane","year":"2013","unstructured":"Shivane A, Parkinson DB, Ammoun S, Hanemann CO . Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas. Histopathology 2013; 62: 651\u2013656.","journal-title":"Histopathology"},{"key":"BFonc2017200_CR65","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/jcbfm.2012.7","volume":"32","author":"T Pflanzner","year":"2012","unstructured":"Pflanzner T, Petsch B, Andre-Dohmen B, Muller-Schiffmann A, Tschickardt S, Weggen S et al. Cellular prion protein participates in amyloid-beta transcytosis across the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32: 628\u2013632.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFonc2017200_CR66","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1006\/nbdi.1998.0179","volume":"5","author":"C Rosenbaum","year":"1998","unstructured":"Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Muller HW, Hanemann CO . Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis 1998; 5: 55\u201364.","journal-title":"Neurobiol Dis"},{"key":"BFonc2017200_CR67","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1021\/jm070688r","volume":"50","author":"A Kimata","year":"2007","unstructured":"Kimata A, Nakagawa H, Ohyama R, Fukuuchi T, Ohta S, Doh-ura K et al. New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation. J Med Chem 2007; 50: 5053\u20135056.","journal-title":"J Med Chem"},{"key":"BFonc2017200_CR68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1750-3639.2008.00165.x","volume":"19","author":"C Flaiz","year":"2009","unstructured":"Flaiz C, Ammoun S, Biebl A, Hanemann CO . Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Brain Pathol 2009; 19: 27\u201338.","journal-title":"Brain Pathol"},{"key":"BFonc2017200_CR69","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/neup.12266","volume":"36","author":"DA Hilton","year":"2016","unstructured":"Hilton DA, Shivane A, Kirk L, Bassiri K, Enki DG, Hanemann CO . Activation of multiple growth factor signalling pathways is frequent in meningiomas. Neuropathology 2016; 36: 250\u2013261.","journal-title":"Neuropathology"},{"key":"BFonc2017200_CR70","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1073\/pnas.0500918102","volume":"102","author":"T Maretzky","year":"2005","unstructured":"Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 2005; 102: 9182\u20139187.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2017200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2017200","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2017.200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/onc2017200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:36:46Z","timestamp":1647895006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2017200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":70,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2017,11,2]]}},"alternative-id":["BFonc2017200"],"URL":"https:\/\/doi.org\/10.1038\/onc.2017.200","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]},"assertion":[{"value":"16 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}